Study on Genentech's eye drugs may affect Medicare

08/28/2008 | Yahoo!

Results from an ongoing study that compares the efficacy of Genentech's Avastin and Lucentis in treating "wet" age-related macular degeneration may affect Medicare coverage of the eye drugs, raising financial stakes for the biotech firm. CMS officials said it would be cheaper to treat patients with Avastin, which costs $60 per treatment, compared with Lucentis, which costs $2,000 per dose. Genentech thinks Lucentis is the best treatment for the condition regardless of the study's outcome, a company spokeswoman said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ